The European peptide therapeutics market will see a considerable growth of 4.3% during the forecast period. The region has a significant presence of peptide therapeutics industry players, with extensive R&D in the market. With the increase in the number of cases of cancer in the region, the demand for proper treatment and availability of drugs is expected to rise; thereby, augmenting the growth of peptide therapeutics for cancer treatment.
Moreover, well-developed healthcare infrastructure is also estimated to surge the adoption of various healthcare facilities in the region. Further, the surging need for early disease diagnosis in the region is supporting the growth of the peptide therapeutics market.
A full report of European Peptide Therapeutics Market is available at: https://www.omrglobal.com/industry-reports/european-peptide-therapeutics-market
Another factor that encourages the growth of the market includes the rising mortality rate from respiratory disorders across the region. As per the Organization For Economic Co-Operation and Development, the self-reported COPD and asthma rates were 4.0% and 6.1% respectively in European Union countries.
Moreover, it has been found that the prevalence rate of diseases is higher in women as compared to men. As per the OECD 2019, respiratory diseases are a major cause of death accounting for 10% of deaths across all OECD countries. COPD accounted for 4% of all deaths globally. Smoking is the main factor that leads to COPD, and occupational exposure to dust, fumes, and chemicals, and air pollution, in general, are also important risk factors. Thus, rising mortalities due to respiratory disorders create a scope for the growth of the market over the forecast period.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/european-peptide-therapeutics-market
Market Coverage
- Study Period- 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segments Covered- By Route of Administration and By Application
- Countries Covered- UK, Germany, Italy, France, Spain, Rest of Europe
- Key Companies Profiled- Novo Nordisk A/S, Eli Lilly & Co., AstraZeneca Plc, CordenPharma International GmbH, Bachem Holding AG, and Sanofi SA
Key questions addressed by the report
- What is the market growth rate during the forecast period?
- Which segment/region dominates the market in the base year?
- Which segment/region will project the fastest growth in the market during the forecast period?
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
European Peptide Therapeutics Market – Segmentation
By Route of Administration
- Oral
- Parenteral
By Application
- Cancer
- Gastrointestinal Disorders
- Central Nervous System Disorders
- Respiratory Disorders
- Others
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
